Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Buspirone HCl (MJ90221, MJ-90221, Buspar, MJ-9022-1, MJ9022 1, MJ9022-1), the hydrochloride salt of Buspirone which is an azapirone anolog, is a potent serotonergic 5HT1A receptor agonist with anti-psychotic effects. Buspirone is a psychotropic anxiolytic that has been approved for use. Generalized anxiety disorder (GAD) is the main condition it is used to treat. Buspirone's pharmacology is unrelated to that of benzodiazepines or barbiturates, unlike most medications used primarily to treat anxiety, so there is no chance of physical dependence or withdrawal symptoms.
Targets |
5-HT1A
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
Cell Line: Lymphocytes
Concentration: 0, 4, 20, 40, 200 and 400 µg/mL Incubation Time: 6 hours Result: Decreased cell viability in a dose-dependent manner. |
|
Animal Protocol |
Male C57BL/6N mice
1 and 5 mg/kg Oral gavage and intraperitoneal injection; for 5 days |
|
References |
Molecular Formula |
C21H32CLN5O2
|
|
---|---|---|
Molecular Weight |
421.96
|
|
Exact Mass |
421.22
|
|
Elemental Analysis |
C, 59.77; H, 7.64; Cl, 8.40; N, 16.60; O, 7.58
|
|
CAS # |
33386-08-2
|
|
Appearance |
White crystalline powder
|
|
SMILES |
C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4.Cl
|
|
InChi Key |
RICLFGYGYQXUFH-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C21H31N5O2.ClH/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20;/h5,8-9H,1-4,6-7,10-17H2;1H
|
|
Chemical Name |
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3699 mL | 11.8495 mL | 23.6989 mL | |
5 mM | 0.4740 mL | 2.3699 mL | 4.7398 mL | |
10 mM | 0.2370 mL | 1.1849 mL | 2.3699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01850355 | Active Recruiting |
Drug: Buspirone | Anxiety Autism Spectrum Disorders |
Massachusetts General Hospital | July 2013 | Not Applicable |
NCT02313194 | Active Recruiting |
Device: Epidural Stimulation Drug: Buspirone |
Tetraparesis Tetraplegia Cervical Spinal Cord Injury |
University of California, Los Angeles |
July 2013 | Phase 1 Phase 2 |
NCT05041322 | Recruiting | Drug: Buspirone Drug: Placebo |
Spinal Cord Injuries | Spaulding Rehabilitation Hospital | November 29, 2020 | Phase 2 |
NCT01821690 | Recruiting | Drug: Buspirone Drug: Placebo |
Traumatic Brain Injury | Indiana University | May 2013 | Not Applicable |
NCT05511909 | Recruiting | Drug: Buspirone Drug: Lofexidine Drug: Placebo |
Opioid Use Disorder Opioid Withdrawal Opioid Craving Anxiety |
Johns Hopkins University | December 15, 2022 | Phase 2 |
Buspirone effects on bottom dwelling (sec/min) in zebrafish (mean ± sem). Pharmacol Biochem Behav . 2009 Nov;94(1):75-80. td> |
Buspirone effects on swimming activity (log cm/min) in zebrafish (mean ± sem). Pharmacol Biochem Behav . 2009 Nov;94(1):75-80. td> |